Department of Endocrinology and Metabolism, The Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Disease, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Eur J Med Res. 2023 Jul 13;28(1):232. doi: 10.1186/s40001-023-01210-7.
Global Coronavir us disease 2019 (COVID-19) vaccination efforts are being intensified to combat the pandemic. As the frequency of immunization against COVID-19 has increased, some adverse effects related to vaccination have emerged. Within this context, this article reviewed 62 Graves' disease (GD) cases following COVID-19 vaccination, to probe the potential association between the vaccination and the onset of GD. A comprehensive search of the PubMed, Web of Science, and Scopus databases was conducted to collect GD cases following COVID-19 vaccination up to June 7, 2023. Among the 62 GD cases included in this review, there were 33 (53.2%) new-onset GD and 10 (16.1%) relapsed GD patients following mRNA vaccination, 14 (22.6%) new-onset GD and 4 (6.5%) relapsed GD patients following viral vector vaccination, and 1 (1.6%) relapsed GD patients following inactivated vaccination. Median durations to symptoms onset for new-onset and relapsed GD were 12 (range: 1-60) and 21 (range: 5-30) days following mRNA vaccination, while 7 (range: 1-28) and 14 (range: 10-14) days following viral vector vaccination, respectively. While the definitive pathogenesis of GD following COVID-19 vaccination remains unclear, it might be associated with cross-immune responses triggered by molecular mimicry, and an adjuvant-induced autoimmune/inflammatory syndrome. However, due to the limited number of observed GD cases following COVID-19 vaccination and the lack of systematic experimental studies, a causal relationship between COVID-19 vaccination and the onset of GD has not been definitively confirmed. It should be highlighted that most of GD patients following COVID-19 vaccination experienced positive outcomes after treatment. In the broader context of ending the COVID-19 pandemic and reducing mortality rates, the benefits of COVID-19 vaccination significantly outweigh mild risks such as treatable GD. Adherence to the COVID-19 vaccination schedule is therefore imperative in effectively managing the pandemic.
全球 2019 年冠状病毒病(COVID-19)疫苗接种工作正在加紧进行,以应对这一大流行病。随着 COVID-19 疫苗接种频率的增加,一些与接种相关的不良反应已经出现。在这种情况下,本文综述了 62 例 COVID-19 疫苗接种后 Graves 病(GD)病例,以探讨疫苗接种与 GD 发病之间的潜在关联。全面检索了 PubMed、Web of Science 和 Scopus 数据库,收集截至 2023 年 6 月 7 日 COVID-19 疫苗接种后发生的 GD 病例。在本综述中纳入的 62 例 GD 病例中,有 33 例(53.2%)为 mRNA 疫苗接种后新发 GD,10 例(16.1%)为复发 GD;14 例(22.6%)为病毒载体疫苗接种后新发 GD,4 例(6.5%)为复发 GD;1 例(1.6%)为灭活疫苗接种后复发 GD。mRNA 疫苗接种后新发和复发 GD 的症状出现中位时间分别为 12(范围:1-60)和 21(范围:5-30)天,而病毒载体疫苗接种后分别为 7(范围:1-28)和 14(范围:10-14)天。虽然 COVID-19 疫苗接种后 GD 的明确发病机制尚不清楚,但可能与分子模拟触发的交叉免疫反应以及佐剂诱导的自身免疫/炎症综合征有关。然而,由于 COVID-19 疫苗接种后观察到的 GD 病例数量有限,并且缺乏系统的实验研究,因此尚未明确证实 COVID-19 疫苗接种与 GD 发病之间存在因果关系。值得强调的是,COVID-19 疫苗接种后大多数 GD 患者在治疗后取得了良好的转归。在结束 COVID-19 大流行和降低死亡率的更广泛背景下,COVID-19 疫苗接种的益处大大超过了可治疗的 GD 等轻度风险。因此,坚持 COVID-19 疫苗接种计划对于有效管理大流行至关重要。